Postpartum thyroid disease: A model of immunologic dysfunction

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Women with underlying, often asymptomatic, thyroid autoimmunity are at risk of developing postpartum thyroid disease/dysfunction (PPTD). While a few cases were reported in the 1800s, the frequent occurrence of PPTD was not described until 1948. Careful delineation of its multiple clinical presentations has emerged only in the past two decades. The sequential increase in cellular immune response at 1-4 months after delivery, followed by a humoral response at 7-10 months, is believed to underlie PPTD in susceptible women. The prevalence of thyroid autoimmunity, determined by positive thyroid peroxidase (TPO) or microsomal antibody titer postpartum, is 10% (range 2.8-26.4%; n = 18). The thyroid antibody test has a sensitivity of 0.71 (0.45-0.89), specificity 0.94 (0.90-0.98) and positive predictive value of 0.57 (0.40-0.78). A small percentage of women have detectable thyroid stimulating or inhibitory antibodies. Clinical expression is variable. Most common is a painless thyroiditis, with a hyperthyroid phase (due to release of stored thyroxine from damaged thyroid follicles) followed by a hypothyroid phase (during repair of the thyroid). This biphasic response is observed in 25% of patients, while the hyperthyroid phase only occurs in 24% and the hypothyroid phase alone in 40%. Sustained hyperthyroidism (Graves' disease) is present in 11% of these women. Management depends on severity and duration of symptoms. Hyperthyroidism due to thyroiditis is often mild and requires no therapy, although a β-blocker may help if adrenergic symptoms are prominent. Hyperthyroidism from Graves' disease requires definitive therapy. Hypothyroidism responds promptly to L-thyroxine (L-T4). While most women recover and can discontinue L-T4 after 6 to 12 months, long-term follow-up indicates that almost 20% of women remain permanently hypothyroid after an episode of PPTD. Optimal detection strategies are not yet defined. Education of health care providers and patients should lead to earlier detection. Laboratory testing of women at increased risk is also recommended.

Original languageEnglish (US)
Pages (from-to)89-103
Number of pages15
JournalClinical and Applied Immunology Reviews
Volume1
Issue number2
DOIs
StatePublished - 2001

Fingerprint

Immunological Models
Thyroid Diseases
Postpartum Period
Hyperthyroidism
Thyroid Gland
Thyroiditis
Graves Disease
Autoimmunity
Thyroxine
Antibodies
Iodide Peroxidase
Hypothyroidism
Cellular Immunity
Health Personnel
Adrenergic Agents
Education

Keywords

  • Autoimmune thyroid disease
  • Fas ligand
  • Postpartum thyroid disease

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Immunology and Allergy
  • Infectious Diseases

Cite this

Postpartum thyroid disease : A model of immunologic dysfunction. / Smallridge, Robert Christian.

In: Clinical and Applied Immunology Reviews, Vol. 1, No. 2, 2001, p. 89-103.

Research output: Contribution to journalArticle

@article{cc312c51a8b14ffcaf99b9c25b2793ae,
title = "Postpartum thyroid disease: A model of immunologic dysfunction",
abstract = "Women with underlying, often asymptomatic, thyroid autoimmunity are at risk of developing postpartum thyroid disease/dysfunction (PPTD). While a few cases were reported in the 1800s, the frequent occurrence of PPTD was not described until 1948. Careful delineation of its multiple clinical presentations has emerged only in the past two decades. The sequential increase in cellular immune response at 1-4 months after delivery, followed by a humoral response at 7-10 months, is believed to underlie PPTD in susceptible women. The prevalence of thyroid autoimmunity, determined by positive thyroid peroxidase (TPO) or microsomal antibody titer postpartum, is 10{\%} (range 2.8-26.4{\%}; n = 18). The thyroid antibody test has a sensitivity of 0.71 (0.45-0.89), specificity 0.94 (0.90-0.98) and positive predictive value of 0.57 (0.40-0.78). A small percentage of women have detectable thyroid stimulating or inhibitory antibodies. Clinical expression is variable. Most common is a painless thyroiditis, with a hyperthyroid phase (due to release of stored thyroxine from damaged thyroid follicles) followed by a hypothyroid phase (during repair of the thyroid). This biphasic response is observed in 25{\%} of patients, while the hyperthyroid phase only occurs in 24{\%} and the hypothyroid phase alone in 40{\%}. Sustained hyperthyroidism (Graves' disease) is present in 11{\%} of these women. Management depends on severity and duration of symptoms. Hyperthyroidism due to thyroiditis is often mild and requires no therapy, although a β-blocker may help if adrenergic symptoms are prominent. Hyperthyroidism from Graves' disease requires definitive therapy. Hypothyroidism responds promptly to L-thyroxine (L-T4). While most women recover and can discontinue L-T4 after 6 to 12 months, long-term follow-up indicates that almost 20{\%} of women remain permanently hypothyroid after an episode of PPTD. Optimal detection strategies are not yet defined. Education of health care providers and patients should lead to earlier detection. Laboratory testing of women at increased risk is also recommended.",
keywords = "Autoimmune thyroid disease, Fas ligand, Postpartum thyroid disease",
author = "Smallridge, {Robert Christian}",
year = "2001",
doi = "10.1016/S1529-1049(00)00008-8",
language = "English (US)",
volume = "1",
pages = "89--103",
journal = "Clinical and Applied Immunology Reviews",
issn = "1529-1049",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Postpartum thyroid disease

T2 - A model of immunologic dysfunction

AU - Smallridge, Robert Christian

PY - 2001

Y1 - 2001

N2 - Women with underlying, often asymptomatic, thyroid autoimmunity are at risk of developing postpartum thyroid disease/dysfunction (PPTD). While a few cases were reported in the 1800s, the frequent occurrence of PPTD was not described until 1948. Careful delineation of its multiple clinical presentations has emerged only in the past two decades. The sequential increase in cellular immune response at 1-4 months after delivery, followed by a humoral response at 7-10 months, is believed to underlie PPTD in susceptible women. The prevalence of thyroid autoimmunity, determined by positive thyroid peroxidase (TPO) or microsomal antibody titer postpartum, is 10% (range 2.8-26.4%; n = 18). The thyroid antibody test has a sensitivity of 0.71 (0.45-0.89), specificity 0.94 (0.90-0.98) and positive predictive value of 0.57 (0.40-0.78). A small percentage of women have detectable thyroid stimulating or inhibitory antibodies. Clinical expression is variable. Most common is a painless thyroiditis, with a hyperthyroid phase (due to release of stored thyroxine from damaged thyroid follicles) followed by a hypothyroid phase (during repair of the thyroid). This biphasic response is observed in 25% of patients, while the hyperthyroid phase only occurs in 24% and the hypothyroid phase alone in 40%. Sustained hyperthyroidism (Graves' disease) is present in 11% of these women. Management depends on severity and duration of symptoms. Hyperthyroidism due to thyroiditis is often mild and requires no therapy, although a β-blocker may help if adrenergic symptoms are prominent. Hyperthyroidism from Graves' disease requires definitive therapy. Hypothyroidism responds promptly to L-thyroxine (L-T4). While most women recover and can discontinue L-T4 after 6 to 12 months, long-term follow-up indicates that almost 20% of women remain permanently hypothyroid after an episode of PPTD. Optimal detection strategies are not yet defined. Education of health care providers and patients should lead to earlier detection. Laboratory testing of women at increased risk is also recommended.

AB - Women with underlying, often asymptomatic, thyroid autoimmunity are at risk of developing postpartum thyroid disease/dysfunction (PPTD). While a few cases were reported in the 1800s, the frequent occurrence of PPTD was not described until 1948. Careful delineation of its multiple clinical presentations has emerged only in the past two decades. The sequential increase in cellular immune response at 1-4 months after delivery, followed by a humoral response at 7-10 months, is believed to underlie PPTD in susceptible women. The prevalence of thyroid autoimmunity, determined by positive thyroid peroxidase (TPO) or microsomal antibody titer postpartum, is 10% (range 2.8-26.4%; n = 18). The thyroid antibody test has a sensitivity of 0.71 (0.45-0.89), specificity 0.94 (0.90-0.98) and positive predictive value of 0.57 (0.40-0.78). A small percentage of women have detectable thyroid stimulating or inhibitory antibodies. Clinical expression is variable. Most common is a painless thyroiditis, with a hyperthyroid phase (due to release of stored thyroxine from damaged thyroid follicles) followed by a hypothyroid phase (during repair of the thyroid). This biphasic response is observed in 25% of patients, while the hyperthyroid phase only occurs in 24% and the hypothyroid phase alone in 40%. Sustained hyperthyroidism (Graves' disease) is present in 11% of these women. Management depends on severity and duration of symptoms. Hyperthyroidism due to thyroiditis is often mild and requires no therapy, although a β-blocker may help if adrenergic symptoms are prominent. Hyperthyroidism from Graves' disease requires definitive therapy. Hypothyroidism responds promptly to L-thyroxine (L-T4). While most women recover and can discontinue L-T4 after 6 to 12 months, long-term follow-up indicates that almost 20% of women remain permanently hypothyroid after an episode of PPTD. Optimal detection strategies are not yet defined. Education of health care providers and patients should lead to earlier detection. Laboratory testing of women at increased risk is also recommended.

KW - Autoimmune thyroid disease

KW - Fas ligand

KW - Postpartum thyroid disease

UR - http://www.scopus.com/inward/record.url?scp=0002672004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002672004&partnerID=8YFLogxK

U2 - 10.1016/S1529-1049(00)00008-8

DO - 10.1016/S1529-1049(00)00008-8

M3 - Article

AN - SCOPUS:0002672004

VL - 1

SP - 89

EP - 103

JO - Clinical and Applied Immunology Reviews

JF - Clinical and Applied Immunology Reviews

SN - 1529-1049

IS - 2

ER -